Pharmaceutical packaging systems are designed to protect products throughout manufacturing, storage, transportation, and patient use. As a result, packaging risk assessments have become a routine part of pharmaceutical development and quality management programs.
However, one important challenge remains: not all packaging-related risks are immediately visible.
While many packaging assessments focus on material compatibility, stability, and regulatory compliance, some evaluations may overlook more complex impurity pathways involving extractables, leachables, and nitrosamine formation. These risks can emerge gradually over time through interactions between packaging materials, drug products, environmental conditions, and degradation processes.
As regulatory scrutiny surrounding pharmaceutical impurities continues to increase, organizations are recognizing that packaging systems should be evaluated not only for product protection but also for their potential contribution to chemical contamination and impurity generation.
At Topiox Research Centre, comprehensive packaging risk assessment is viewed as an essential component of pharmaceutical quality, product safety, and lifecycle risk management.
Can Packaging Risk Assessments Miss Nitrosamine or Leachable Risk?
Yes. Packaging risk assessments may overlook nitrosamine or leachable risks if evaluations focus only on material compatibility and fail to consider extractables, long-term storage conditions, degradation pathways, container closure interactions, and lifecycle impurity formation. Comprehensive risk assessment requires a broader evaluation of how packaging materials interact with pharmaceutical products over time.
Quick Takeaway
A packaging system that appears acceptable during initial evaluation may still contribute to extractable migration, leachable formation, or nitrosamine-related risks during storage. Integrating extractables and leachables testing, stability studies, and impurity risk assessment can help identify risks that traditional packaging evaluations may miss.
Where Packaging Risk Assessments Commonly Miss Risk
Even well-designed packaging risk assessments can overlook impurity pathways when evaluations focus primarily on material compatibility and initial qualification activities.
The three most common gaps include:
1. Limited Evaluation of Extractables and Leachables
Potential migrating compounds may not be fully characterized during early packaging assessments.
2. Insufficient Long-Term Storage Assessment
Certain impurity pathways emerge gradually and may only become apparent during stability studies.
3. Underestimating Nitrosamine Formation Pathways
Packaging-derived compounds, degradation products, and formulation interactions may create conditions that contribute to nitrosamine-related risks over time.
Addressing these areas can strengthen packaging risk assessments and support more comprehensive pharmaceutical quality management.
Why Packaging Risk Assessments Matter
Packaging systems serve several critical functions:
- Protect product quality
- Maintain product stability
- Prevent contamination
- Support shelf life
- Ensure patient safety
Because packaging materials remain in direct or indirect contact with pharmaceutical products for extended periods, even trace chemical interactions can become significant over time.
For this reason, packaging risk assessments are an important component of pharmaceutical development and regulatory compliance programs.
Understanding Extractables and Leachables
Although often discussed together, extractables and leachables are not the same.
Extractables
Extractables are chemical compounds that can be released from packaging materials under aggressive laboratory extraction conditions.
Potential sources include:
- Plastic components
- Elastomers
- Rubber stoppers
- Adhesives
- Coatings
- Printing inks
Extractables studies help identify compounds that could potentially migrate into a pharmaceutical product.
Leachables
Leachables are compounds that actually migrate from packaging systems into the drug product under normal storage conditions.
Because leachables represent real-world exposure, they are often considered more directly relevant to product safety and quality.
Why Nitrosamine Risk Is Often Evaluated Separately
Nitrosamines have become a major focus of pharmaceutical risk management due to their potential carcinogenic properties.
Historically, nitrosamine investigations focused primarily on:
- API synthesis
- Raw materials
- Solvents
- Manufacturing processes
However, growing evidence suggests that packaging systems and storage conditions may also contribute to nitrosamine formation pathways in certain circumstances.
This has expanded the scope of nitrosamine risk assessment beyond manufacturing activities alone.
Where Packaging Risk Assessments Commonly Miss Risk
Focusing Only on Material Compatibility
Many packaging evaluations emphasize physical compatibility while giving less attention to long-term chemical interactions.
A material that appears physically stable may still contribute to impurity formation under specific conditions.
Evaluating Packaging Components Independently
Individual packaging materials may appear low risk when assessed separately.
However, interactions between:
- Drug products
- Packaging components
- Degradation products
- Environmental conditions
can create additional impurity pathways that are not obvious during isolated evaluations.
Underestimating Long-Term Storage Effects
Certain impurity pathways develop slowly.
Products that initially meet quality specifications may experience gradual increases in leachables or impurity levels during storage.
Overlooking Nitrosamine Precursors
Some packaging-related compounds may not be nitrosamines themselves but could contribute to nitrosamine formation under suitable chemical conditions.
Limited Lifecycle Assessment
Risk assessments focused solely on development-stage evaluations may fail to account for changes that occur throughout product storage and commercialization.
Packaging Risk Assessment vs Comprehensive Lifecycle Assessment
| Traditional Packaging Assessment | Comprehensive Lifecycle Assessment |
| Material compatibility focus | Product–packaging interaction focus |
| Initial evaluation emphasis | Lifecycle monitoring emphasis |
| Packaging performance review | Impurity formation pathway review |
| Physical stability focus | Chemical stability focus |
| Component-level evaluation | System-level evaluation |
| Short-term assessment | Long-term storage assessment |
This broader perspective can help identify risks that may not be apparent during routine packaging qualification activities.
The Relationship Between Extractables, Leachables, and Nitrosamines
Although extractables, leachables, and nitrosamines are often evaluated through separate programs, they can be interconnected.
Potential pathways include:
- Packaging materials contain extractable compounds.
- Extractables migrate into the product and become leachables.
- Leachables interact with formulation components.
- Degradation processes occur during storage.
- Conditions emerge that may contribute to nitrosamine formation.
Not every packaging system follows this pathway, but understanding these relationships helps strengthen pharmaceutical risk assessments.
Topiox 4-Part Framework for Packaging-Related Impurity Risk Assessment
A comprehensive packaging risk assessment should evaluate four key areas:
1. Packaging Material Assessment
Review packaging materials, elastomers, polymers, coatings, and container closure systems.
2. Extractables and Leachables Evaluation
Identify compounds capable of migrating into the pharmaceutical product.
3. Storage and Stability Assessment
Evaluate the impact of temperature, humidity, light exposure, and shelf-life duration.
4. Nitrosamine and Impurity Risk Review
Assess potential impurity formation pathways involving packaging interactions, degradation products, and precursor compounds.
By evaluating all four areas together, manufacturers can develop a more complete understanding of packaging-related risks.
Key Questions for Packaging-Related Impurity Risk Assessment
Before finalizing a packaging risk assessment, manufacturers should consider:
- Have all packaging materials and container closure systems been evaluated?
- Have extractables and leachables studies been performed where appropriate?
- Could storage conditions influence impurity formation?
- Are degradation products being monitored during stability studies?
- Have potential nitrosamine formation pathways been assessed?
- Is lifecycle monitoring included within the overall control strategy?
These questions help ensure that packaging assessments extend beyond material compatibility and address broader product quality considerations.
Example: How Packaging Risks Can Be Missed
Consider a pharmaceutical product packaged in a container closure system that successfully passes initial compatibility testing.
At product release, impurity levels remain within specification.
However, during long-term stability studies, trace packaging-derived compounds migrate into the formulation. These compounds interact with degradation products generated during storage, creating conditions that contribute to impurity formation.
Without extractables and leachables testing, stability monitoring, and impurity-focused risk assessment, these risks may not be identified until later in the product lifecycle.
Practical Investigation Insight
In packaging-related impurity investigations, unexpected findings are often associated with the interaction of multiple factors rather than a single isolated source. For example, a packaging material may demonstrate acceptable compatibility during development, yet long-term storage conditions combined with formulation degradation can create impurity pathways that were not initially anticipated.
This is why modern extractables and leachables testing programs increasingly incorporate stability considerations, risk-based study design, and lifecycle monitoring rather than relying solely on initial packaging qualification data.
Regulatory Expectations for Packaging-Related Risk Assessment
Regulatory authorities increasingly expect manufacturers to evaluate pharmaceutical products using a science-based and risk-based approach.
This includes consideration of:
- Packaging systems
- Container closure systems
- Extractables and leachables
- Product stability
- Impurity control strategies
- Lifecycle monitoring
Comprehensive packaging assessments support product safety, quality assurance, and regulatory readiness.
How Topiox Research Centre Supports Extractables, Leachables, and Packaging Risk Assessment
At Topiox Research Centre, packaging-related risk assessments extend beyond traditional compatibility studies.
Our support may include:
- Extractables and leachables testing
- Packaging compatibility assessments
- Container closure evaluations
- Stability study support
- Nitrosamine risk assessment
- Analytical method development
- Impurity investigations
- Regulatory-focused reporting
In practical investigations, packaging-related impurity risks are often associated with the combined effects of packaging materials, formulation characteristics, degradation pathways, and storage conditions rather than a single isolated factor.
By integrating analytical science, risk assessment, and lifecycle monitoring, organizations can strengthen packaging qualification programs and reduce the likelihood of unexpected impurity findings.
Learn more about our Extractables and Leachables Testing Services and packaging risk assessment capabilities.
Faq's
Extractables are compounds that can be released from packaging materials under laboratory extraction conditions, while leachables are compounds that actually migrate into the pharmaceutical product during normal storage.
Potentially. Certain packaging-related compounds may contribute to impurity formation pathways under specific conditions, particularly when combined with degradation products and suitable storage environments.
These studies help identify compounds that may affect product safety, stability, quality, or regulatory compliance.
Yes. Some impurity pathways emerge gradually during storage and may not be apparent during initial compatibility assessments.
A comprehensive approach typically includes packaging assessment, extractables and leachables testing, stability studies, impurity risk assessment, and ongoing lifecycle monitoring.
Not necessarily in every case, but extractables and leachables may contribute to chemical environments or impurity pathways that warrant further nitrosamine risk evaluation.
No. Packaging compatibility studies and extractables and leachables testing serve different purposes. Compatibility studies evaluate interactions between packaging and the product, while extractables and leachables testing helps identify and characterize chemical compounds that may migrate from packaging materials into pharmaceutical products.
